吉西他滨联合化疗治疗复发或转移性乳腺癌

doi:10.3760/cma.j.issn.1673-422X.2015.10.014

摘要/Abstract

摘要： 吉西他滨联合化疗是治疗复发或转移性乳腺癌的有效方案。除了标准的联合紫杉醇3周方案之外，根据个体化治疗原则，也可选择不同的联合药物如多西他赛或铂类，或是采取不同的给药频率和剂量以及延长给药周期进行维持。吉西他滨联合紫杉类药物对于有内脏转移、激素受体阴性的患者临床获益更加明显，初步循证结果证明了后续进行同方案维持治疗的可行性。另外，吉西他滨联合顺铂方案是治疗转移性三阴乳腺癌更优的选择。

关键词: 乳腺肿瘤, 药物疗法, 吉西他滨

Abstract: Gemcitabine based chemotherapy is effective in recurrent or metastatic breast cancer. Besides the 3 week regimen in combination with paclitaxel, individualized treatments are also applied to combine gemcitabine with other agents such as docetaxel or platinum, or to administer by different frequency or dose, or to continuously maintain on the treatment as an extension to front line. It is demonstrated that gemcitabine in combination with taxanes can obtain survival benefit, largely in patients with visceral metastasis or hormone receptor negative. Initial evidence has also supported the feasibility of continuous maintenance. Finally, gemcitabine in combination with cisplatin is a better option for the metastatic triple negative breast cancer.

Key words: Breast neoplasms, Drug therapy, Gemcitabine

佟仲生,徐聪,王晋. 吉西他滨联合化疗治疗复发或转移性乳腺癌[J]. 国际肿瘤学杂志, 2015, 42(10): 769-772.

Tong Zhongsheng, Xu Cong, Wang Jin. Gemcitabine in combination with chemotherapy in the treatment of recurrent or metastatic breast cancer[J]. Journal of International Oncology, 2015, 42(10): 769-772.

参考文献

［1］ Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010［J］. Chin J Cancer Res, 2014, 26(1): 48-58. ［2］ O′Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer［J］. Oncologist, 2005, 10 Suppl 3: 20-29. ［3］ Ferrazzi E, Stievano L. Gemcitabine: monochemotherapy of breast cancer［J］. Ann Oncol, 2006, 17 Suppl 5: v169-172. ［4］ Zupi G, Scarsella M, D′Angelo C, et al. Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells ［J］. Cancer Biol Ther, 2005, 4(8): 866-871. ［5］ Ricotti L, Tesei A, De Paola F, et al. In vitro scheduledependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines［J］. Clin Cancer Res, 2003, 9(2): 900-905. ［6］ Albain KS, Nag SM, CalderilloRuiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment［J］. J Clin Oncol, 2008, 26(24): 3950-3957. ［7］ Moinpour C, Wu J, Donaldson G, et al. Gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as firstline therapy for anthracycline pretreated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase Ⅲ study ［C］. J Clin Oncol, 2004, 22(14S):621. ［8］ Xu B, Shen Z, Jiang Z, et al. A phase Ⅱ study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment［J］. Asia Pac J Clin Oncol, 2010, 6(4): 320-329. ［9］ Xu B, Zhang XQ, Chi HD, et al. Consistent efficacy and safety of gemcitabinepaclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies［J］. Asia Pac J Clin Oncol, 2014, 10(4): 330-339. ［10］ Park YH, Jung KH, Im SA, et al. Phase Ⅲ, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as firstline chemotherapy: KCSGBR0702［J］. J Clin Oncol, 2013, 31(14): 1732-1739. ［11］ Colomer R, LlombartCussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase Ⅱ trial and predictive value of HER2 extracellular domain［J］. Ann Oncol, 2004, 15(2): 201-206. ［12］ Xu B, Jiang Z, Kim SB, et al. Biweekly gemcitabinepaclitaxel, gemcitabinecarboplatin, or gemcitabinecisplatin as firstline treatment in metastatic breast cancer after anthracycline failure: a phase Ⅱ randomized selection trial［J］. Breast Cancer, 2011, 18(3): 203-212. ［13］ Seidman AD, Berry D, Cirrincione C, et al. Randomized phase Ⅲ trial of weekly compared with every3weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840［J］. J Clin Oncol, 2008, 26 (10): 1642-1649. ［14］ Del Mastro L, Fabi A, Mansutti M, et al. Randomized phase 3 openlabel trial of firstline treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments［J］. BMC Cancer, 2013, 13: 164-174. ［15］ Chan S, Romieu G, Huober J, et al. Phase Ⅲ study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracyclinepretreated patients with metastatic breast cancer［J］. J Clin Oncol, 2009, 27(11): 1753-1760. ［16］ Seidman AD, Brufsky A, Ansari RH, et al. Phase Ⅲ trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer［J］. Ann Oncol, 2011, 22(5): 1094-1101. ［17］ Karachaliou N, Kouroussis Ch, Papakotoulas P, et al. A multicenter phase Ⅱ trial of docetaxel plus gemcitabine as salvage treatment in anthracycline and taxanepretreated patients with metastatic breast cancer［J］. Cancer Chemother Pharmacol, 2012, 69(5): 1345-1352. ［18］ Murialdo R, Bertolotti F, Pastorino G, et al. Biweekly docetaxel and gemcitabine regimen in her2negative and anthracyclinepretreated metastatic breast cancer patients: a multicenter phase Ⅱ trial［J］. Cancer Chemother Pharmacol, 2011, 68(4): 1009-1016. ［19］ Pelegrí A, Calvo L, Antón A, et al. Docetaxel/gemcitabine administered every other week as firstline treatment for metastatic breast cancer: final results of a phase Ⅱ trial［J］. Clin Breast Cancer, 2005, 6(5): 433-438. ［20］ Papadimitriou CA, Kalofonos H, Zagouri F, et al. Weekly docetaxel with or without gemcitabine as secondline chemotherapy in paclitaxelpretreated patients with metastatic breast cancer: a randomized phase Ⅱ study conducted by the Hellenic CoOperative Oncology Group［J］. Oncology, 2009, 77(34): 212-216. ［21］ O′Shaughnessy JA, Pluenneke R, Sternberg J, et al. Phase Ⅱ trial of weekly docetaxel/gemcitabine as firstline chemotherapy in patients with locally recurrent or metastatic breast cancer［J］. Clin Breast Cancer, 2006, 6(6): 505-510. ［22］ Palmeri S, Vaglica M, Spada S, et al. Weekly docetaxel and gemcitabine as firstline treatment for metastatic breast cancer: results of a multicenter phase Ⅱ study ［J］. Oncology, 2005, 68(46): 438-445. ［23］ Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as firstline therapy for metastatic triplenegative breast cancer (CBCSG006): a randomized, openlabel, multicenter, phase 3 trial［J］. Lancet Oncol, 2015, 16(4): 436-446. ［24］ Ciruelos EM, Cortés J, CortésFunes H, et al. Gemcitabine and capecitabine in previously anthracyclinetreated metastatic breast cancer: a multicenter phase Ⅱ study (SOLTI 0301 trial)［J］. Ann Oncol, 2010, 21(7): 1442-1447. ［25］ Aapro MS, Martin C, Hatty S. Gemcitabine—a safety review［J］. Anticancer Drugs, 1998, 9(3): 191-201. ［26］ Ho MY, Mackey JR. Presentation and management of docetaxelrelated adverse effects in patients with breast cancer［J］. Cancer Manag Res, 2014, 6: 253-259. ［27］ Hartmann JT, Lipp HP. Toxicity of platinum compounds［J］. Expert Opin Pharmacother, 2003, 4(6): 889-901.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[7]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[12]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[15]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.